Home » Stocks » Delcath Systems

Delcath Systems, Inc. (DCTH)

Stock Price: $10.75 USD -0.64 (-5.62%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 43.97M
Revenue (ttm) 1.57M
Net Income (ttm) -7.22M
Shares Out 4.09M
EPS (ttm) -12.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $10.75
Previous Close $11.39
Change ($) -0.64
Change (%) -5.62%
Day's Open 11.31
Day's Range 10.71 - 11.51
Day's Volume 44,237
52-Week Range 5.15 - 14.00

More Stats

Market Cap 43.97M
Enterprise Value 30.30M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 4.09M
Float 3.52M
EPS (basic) -519.97
EPS (diluted) -12.88
FCF / Share -13.66
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 138,714
Short Ratio 3.94
Short % of Float 3.94%
Beta 0.38
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 28.01
PB Ratio 6.11
Revenue 1.57M
Operating Income -19.45M
Net Income -7.22M
Free Cash Flow -31.05M
Net Cash 13.67M
Net Cash / Share 3.34
Gross Margin 54.84%
Operating Margin -1,239.04%
Profit Margin -459.70%
FCF Margin -1,977.90%
ROA -93.24%
ROE n/a
ROIC 62.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(81.40% upside)
Current: $10.75
Target: 19.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-53.62%25.49%-
Gross Profit0.862.402.01
Operating Income-19.91-27.07-18.17
Net Income-8.88-19.22-45.12
Shares Outstanding0.030.04-
Earnings Per Share-1,047.00-504.00-2,275,000.00
Operating Cash Flow-23.69-14.73-15.40
Capital Expenditures-0.02-0.08-0.52
Free Cash Flow-23.71-14.81-15.92
Cash & Equivalents10.183.585.32
Total Debt2.862.04-
Net Cash / Debt7.321.545.32
Book Value-6.36-14.940.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Delcath Systems, Inc.
Country United States
Employees 33
CEO Gerard J. Michel

Stock Information

Ticker Symbol DCTH
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: DCTH


Delcath Systems, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.